Click on image to view larger version.

Figure 1 Diagram of INVEST plan. Patients are randomized (R) at visit 1 (0) to either a calcium antagonist antihypertensive care strategy (bottom) or the noncalcium antagonist antihypertensive care strategy (top). Initial study drug assignments would include verapamil SR or atenolol, respectively. The doses provided are recommended but can be modified by the prescription on the basis of the physician’s knowledge of the patient’s condition (see Fig. 2). The patient’s return for follow-up titration visits (T) at 6, 12 and 18 weeks, when additional drugs or doses can be utilized as outlined. ( ) shows maximal dose of trandolapril offered.